A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 465 participants.
Also called NCT06717698
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 465 participants
- Sponsor
- Registry
-
NCT06717698
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Brazil, Bulgaria, Czechia, India, Italy, Japan, Malaysia, Poland, South Korea, Spain, Türkiye
- Registry status
- Recruiting
Technical summary
Registry record NCT06717698. Randomized; quadruple masking; primary purpose treatment. Start 2024-12-02 (actual); primary completion 2026-09-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- NNC0519-0130
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Semaglutide
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct06717698- Content hash
456fda65ced4ca4a4784f9c2c17f4ce03bdb5c7d05b5dcc6429905a44b795e35